why choose us

First received: March 28, 2023

Clinical Trial: Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Study Type: INTERVENTIONAL


Official Title: Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)

Brief Summary: Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

Read more